Kintor Pharma, maker of China’s leading candidate for a pill-based Covid-19 treatment, will seek to amend late-trial protocols for further testing. Photo: Shutterstock
Kintor Pharma, maker of China’s leading candidate for a pill-based Covid-19 treatment, will seek to amend late-trial protocols for further testing. Photo: Shutterstock

China race for Covid-19 pill treatment hit by low hospital cases

  • Late-stage clinical trials for Kintor Pharma’s experimental drug misses statistical criteria because of ‘changing conditions’ in US
  • But analysis shows no safety concerns and no serious adverse events for the drug, which is being tested in several countries

Topic |   Coronavirus pandemic
Kintor Pharma, maker of China’s leading candidate for a pill-based Covid-19 treatment, will seek to amend late-trial protocols for further testing. Photo: Shutterstock
Kintor Pharma, maker of China’s leading candidate for a pill-based Covid-19 treatment, will seek to amend late-trial protocols for further testing. Photo: Shutterstock
READ FULL ARTICLE